Floatz logo

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS

Solid Tumor

ImmunityBio, Inc.Cell therapyPhase 1Dormant
D
25/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
59/ 100

Competitive context

480 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
Mirati Therapeutics Inc.
Phase 4BB
(+)-VINCRISTINE
Pfizer
Phase 4B
Atezolizumab
Hoffmann-La Roche
Phase 2/3B
Rivoceranib
Beidahuang Industry Group General Hospital
Phase 3B
Durvalumab
GlaxoSmithKline
Phase 4B

View all 50 →

Same molecule, other indications

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →